ANL Adlai Nortye Group Ltd. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1944552 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $5.00M |
| R&D expense | $44.91M | $58.15M |
| SG&A expense | $9.95M | $15.29M |
| Operating income | -$52.93M | -$72.55M |
| Interest expense | $1.94M | $791,000 |
| Pretax income | -$51.87M | -$109.23M |
| Income tax | — | $643,000 |
| Net income | -$51.87M | -$109.23M |
| EBITDA | -$52.42M | -$72.09M |
| EPS (basic) | -0.54 | -2.52 |
| EPS (diluted) | -0.54 | -2.52 |
| Weighted avg. shares (diluted) | 95.78M | 43.34M |
| Balance sheet | ||
| Cash & equivalents | $60.90M | $91.49M |
| Current assets | $64.06M | $101.19M |
| PP&E, netmay include right-of-use assets (IFRS) | $1.74M | $2.65M |
| Intangibles | $40,000 | $63,000 |
| Total assets | $71.27M | $130.19M |
| Current liabilities | $45.36M | $49.67M |
| Short-term debt | $26.33M | $30.36M |
| Total liabilities | $45.78M | $55.14M |
| Shareholders' equity | $25.48M | $75.05M |
| Cash flow statement | ||
| Operating cash flow | -$51.82M | -$56.65M |
| Capital expenditure | $170,000 | $200,000 |
| Free cash flow | -$51.99M | -$56.85M |
| Investing cash flow | $28.07M | -$10.95M |
| Financing cash flow | -$6.58M | $116.24M |
| Depreciation & amortization | $510,000 | $465,000 |
| Stock-based compensation | $2.45M | $4.33M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.